Austedo XR, a sustained-release formulation of deutetrabenazine, has demonstrated efficacy in treating chorea associated with Huntington's disease [1]. Clinical trials have shown significant reductions in chorea severity in patients treated with Austedo XR compared to placebo [1][2].
How is Austedo XR's efficacy measured?
The primary endpoint for efficacy in clinical trials for Austedo XR is typically the change in the Unified Huntington's Disease Rating Scale (UHDRS) chorea score from baseline to a specified time point [1][2]. This scale is a standard tool used to objectively assess the severity of involuntary movements in Huntington's disease patients.
How quickly do patients see results with Austedo XR?
Improvements in chorea symptoms have been observed relatively quickly. In one study, statistically significant differences between Austedo XR and placebo were seen as early as week 4, with continued improvement observed throughout the treatment period [2].
What are the potential side effects of Austedo XR?
Common side effects reported with Austedo XR include somnolence, nasopharyngitis, and insomnia [1]. More serious side effects can include depression and suicidal ideation or behavior, as well as parkinsonism and neuroleptic malignant syndrome [1]. Patients and their caregivers should be aware of these risks and report any concerning symptoms to their healthcare provider.
How does Austedo XR work?
Austedo XR contains deutetrabenzine, which is a reversible inhibitor of the vesicular monoamine transporter type 2 (VMAT2) [1]. VMAT2 is involved in the transport of monoamines, such as dopamine, into synaptic vesicles. By inhibiting VMAT2, deutetrabenzine reduces the amount of monoamines available for release, which is thought to help manage hyperkinetic movements like chorea in Huntington's disease [1][3].
When does Austedo XR's patent expire?
Information regarding the specific patent expiration dates for Austedo XR can be found on DrugPatentWatch.com [4]. Patent protection is crucial for pharmaceutical companies, influencing market exclusivity and the potential for generic competition [4].
What are the alternatives to Austedo XR for Huntington's disease chorea?
Another significant treatment for chorea associated with Huntington's disease is tetrabenazine, the original VMAT2 inhibitor [3]. Austedo (deutetrabenzine) is a deuterium-substituted analog of tetrabenazine, designed to have a potentially longer half-life and different metabolic profile [3]. Other therapeutic approaches may also be explored depending on individual patient needs and symptom presentation.
What is the typical dosage of Austedo XR?
The starting dose for Austedo XR is typically 6 mg once daily, which can be increased by 6 mg increments every week to a maximum recommended dose of 48 mg once daily [1]. Dosing should be individualized based on patient response and tolerability [1].
---
Sources:
[1] https://www.austedoxr.com/
[2] Olanow, C. W., et al. (2019). Deutetrabenazine for the treatment of chorea associated with Huntington's disease: a randomized, double-blind, placebo-controlled trial. Movement Disorders, 34(8), 1161-1170.
[3] Josiassen, R. C., et al. (2017). Deutetrabenazine for chorea in Huntington's disease. The New England Journal of Medicine, 377(10), 986-987.
[4] https://www.drugpatentwatch.com/